Breaking News

Grand River Aseptic to Expand in West Michigan

June 16, 2014

A group of independent investors, led by the Municipal Employees' Retirement System of Michigan, has invested $9.8 million in Grand River Aseptic Manufacturing

A group of Michigan and Indiana based investors, led by the Municipal Employees' Retirement System (MERS) of Michigan, has invested $9.8 million in Grand River Aseptic Manufacturing (GRAM), a contract manufacturer of sterile injectable pharmaceuticals that offers services for aseptic vial and syringe filling. The company plans to use the funds to expand its range of services and hire additional staff.  "We are delighted with the strong investor response, especially by MERS," said GRAM president Tom Ross. "Their considerable support, in combination with backing from many private investors in our community, is a strong indicator that we're headed in the right direction.  This funding enables us to expand our capabilities, improve our facility and advance our customer reach, all while creating more highly technical, high-paying jobs in west Michigan.  We have a great company, fantastic employees and a bright future," he said.

MERS of Michigan is one of the 200 largest pension funds in the U.S., with an investment program that is reportedly worth nearly $9 billion.  "We are proud to be investing in Michigan's renaissance," said Jeb Burns, MERS Chief Investment Officer. "GRAM represents a unique opportunity right here at home---world class talent, a blue chip roster of customers and advanced manufacturing that will lead our state's economy.  We're excited to grow alongside this Michigan company."

GRAM offers services including sterile product development and manufacture, lyophilization, terminal sterilization, vial and syringe filling, as well as analytical and microbiological services. 

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks